PDIK1L Inhibitors
Chemical inhibitors of PDIK1L can affect its function through various mechanisms, primarily by competing with ATP for the binding site or by interfering with the kinase's activation pathway. Staurosporine, known for its broad-spectrum kinase inhibition, can bind to the ATP-binding pocket of PDIK1L, thus obstructing the ATP required for phosphorylation of substrates. Similarly, Bisindolylmaleimide I, which is a selective inhibitor of protein kinase C, could potentially inhibit PDIK1L in a comparable manner due to the structural homology with kinases. H-89, which targets protein kinase A, is another example that can inhibit PDIK1L through preventing ATP from binding to the kinase. LY294002 and Wortmannin, both inhibitors of phosphoinositide 3-kinases, can interfere with PI3K signaling pathways, which may be a prerequisite for PDIK1L's kinase activity.
Moreover, SP600125, which inhibits the c-Jun N-terminal kinase, can impede the phosphorylation events mediated by JNK, which may be essential for PDIK1L activation. U0126, an inhibitor of MEK1/2 in the MAPK/ERK pathway, can halt the downstream signaling required for PDIK1L function. SB203580 specifically inhibits p38 MAP kinase, and if PDIK1L activity is mediated by this pathway, its function can be inhibited. Lapatinib, which targets the EGFR and HER2/neu tyrosine kinases, can also inhibit PDIK1L if it is activated by pathways involving these receptors. Imatinib Mesylate, which targets tyrosine kinases like BCR-ABL, c-Kit, and PDGFR, and Dasatinib, which inhibits BCR-ABL and Src family kinases, can prevent the phosphorylation necessary for PDIK1L's activation if it is indeed regulated by these kinases. Lastly, Sorafenib, which targets various receptor tyrosine kinases involved in cell signaling, can inhibit PDIK1L if it is part of a signaling cascade involving these receptors. Each inhibitor has a unique mode of action, but all ultimately converge on the common goal of impeding PDIK1L's kinase activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, and PDIK1L is a kinase-like protein. Staurosporine inhibits PDIK1L by binding to its ATP-binding pocket, thus preventing ATP from binding and the subsequent phosphorylation of substrates. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I is a specific inhibitor of protein kinase C (PKC), and since PDIK1L has homology to kinases, it might share a similar sensitivity to PKC inhibitors. Bisindolylmaleimide I would inhibit PDIK1L by competing with ATP at the binding site. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). If PDIK1L is involved in the PI3K signaling pathway, LY294002 would inhibit PDIK1L by blocking the PI3K-dependent phosphorylation steps necessary for its activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). If PDIK1L is part of a signaling cascade involving JNK, SP600125 would inhibit PDIK1L's function by blocking the phosphorylation events mediated by JNK that are required for PDIK1L activation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, key proteins in the MAPK/ERK pathway. If PDIK1L is modulated by the MAPK/ERK pathway, U0126 would inhibit PDIK1L by preventing the activation of MEK1/2 and subsequent signaling events necessary for PDIK1L function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase. If PDIK1L activity is mediated by p38 MAP kinase signaling, SB203580 would inhibit PDIK1L by blocking the kinase activity of p38 MAP kinase that might be upstream of PDIK1L. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K. If PDIK1L's activity is related to the PI3K/Akt pathway, Wortmannin could inhibit PDIK1L by blocking PI3K and thus preventing the downstream activation of Akt and other kinases that may regulate PDIK1L. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib is a dual tyrosine kinase inhibitor that targets EGFR and HER2/neu. If PDIK1L is activated in a pathway involving these receptors, Lapatinib would inhibit PDIK1L by preventing the receptor phosphorylation and activation that may be necessary for PDIK1L function. | ||||||
Imatinib mesylate | 220127-57-1 | sc-202180 sc-202180A | 25 mg 100 mg | $44.00 $109.00 | 61 | |
Imatinib Mesylate is a tyrosine kinase inhibitor that specifically targets BCR-ABL, c-Kit, and PDGFR. If PDIK1L is involved in pathways regulated by these kinases, Imatinib Mesylate would inhibit PDIK1L by blocking the tyrosine kinase activity necessary for PDIK1L's activation. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a kinase inhibitor that targets several receptor tyrosine kinases (RTKs) involved in tumor growth and angiogenesis. If PDIK1L is part of a pathway involving these RTKs, Sorafenib would inhibit PDIK1L by blocking the activity of these kinases, thereby inhibiting PDIK1L's function. | ||||||